Nerve Growth Factor (NGF): The Original Neurotrophic Peptide
Neurotrophic Peptides
69.6%
Corneal healing rate with cenegermin, the first FDA-approved recombinant NGF drug, compared to 29.4% with vehicle alone.
Bonini et al., Ophthalmology, 2018
Bonini et al., Ophthalmology, 2018
View as imageNerve growth factor was the first neurotrophin ever identified. Rita Levi-Montalcini and Stanley Cohen shared the 1986 Nobel Prize in Physiology or Medicine for discovering it, and their work launched an entire field of research into how proteins regulate neuronal survival, growth, and repair.[1] Nearly four decades later, NGF remains one of the most studied peptide signaling molecules in neuroscience. It has produced one FDA-approved drug, shaped our understanding of neurotrophic peptides, and generated billions of dollars in failed clinical programs. The gap between what NGF does in the lab and what it can do in patients is one of the most instructive stories in peptide therapeutics. As the founding member of the neurotrophin family that includes BDNF, NGF set the template for how we think about brain-protective proteins.
Key Takeaways
- NGF was the first neurotrophin discovered in the 1950s, earning the 1986 Nobel Prize and launching the neurotrophic factor field
- Cenegermin (Oxervate), a recombinant NGF eye drop, achieved 69.6% corneal healing vs. 29.4% for placebo in neurotrophic keratitis trials
- Tanezumab, an anti-NGF antibody for chronic pain, was discontinued in 2021 after joint safety concerns surfaced in phase 3 trials
- NGF gene therapy for Alzheimer's disease showed biological activity in phase 1 but failed to improve clinical outcomes in a phase 2 trial of 49 patients
- Cerebrolysin, a peptide mixture, increases NGF and BDNF levels in aging rat brains, suggesting peptide-based approaches to neurotrophic support
- Semax, an ACTH analog, specifically binds and increases NGF and BDNF expression in rat hippocampus and basal forebrain
What Is Nerve Growth Factor?
NGF is a 26-kilodalton homodimeric protein belonging to the neurotrophin family. The biologically active form is the beta subunit of a larger 7S complex. Its three-dimensional structure features a cystine knot motif: two disulfide bridges form a ring that a third disulfide bridge passes through, creating exceptional structural stability.[2]
The neurotrophin family includes four members: NGF, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). Each binds preferentially to a specific Trk receptor while also binding the shared p75NTR receptor. NGF's primary high-affinity receptor is TrkA.
NGF is produced by target tissues that neurons innervate. Sympathetic neurons, sensory neurons of the dorsal root ganglia, and cholinergic neurons of the basal forebrain all depend on NGF for survival during development. In adults, NGF shifts from a survival factor to a maintenance and plasticity regulator, though its role in pain sensitization becomes increasingly prominent.
The protein is synthesized as a larger precursor called proNGF, which is cleaved to produce mature NGF. This distinction matters clinically: proNGF and mature NGF activate different signaling cascades and can produce opposing effects. ProNGF preferentially binds p75NTR and sortilin, driving cell death pathways, while mature NGF preferentially activates TrkA to promote survival.[3]
How NGF Signals Through TrkA and p75NTR
NGF's biological effects flow through two receptor systems that can cooperate or oppose each other.
TrkA: The Survival Receptor
When mature NGF binds TrkA, the receptor dimerizes and autophosphorylates, triggering three major intracellular cascades. The PI3K/AKT pathway promotes cell survival by inhibiting apoptotic proteins. The MAPK/ERK pathway drives gene expression changes that support neuronal differentiation and axon growth. The PLC-gamma pathway modulates calcium signaling and synaptic function.[4]
A distinctive feature of NGF-TrkA signaling is retrograde transport. NGF binds TrkA at nerve terminals, and the complex is internalized into signaling endosomes that travel along axons back to the cell body. This mechanism allows target-derived NGF to regulate gene expression in neurons whose cell bodies are centimeters or even a meter away from their terminals.
p75NTR: Context-Dependent Signaling
The p75 neurotrophin receptor binds all neurotrophins with similar affinity. When TrkA is present, p75NTR enhances NGF binding specificity and strengthens survival signaling. When TrkA is absent, p75NTR can recruit adaptor proteins that activate NF-kB (promoting survival) or JNK and caspase cascades (promoting apoptosis).
This dual receptor system creates a biological switch. Cells expressing both TrkA and p75NTR respond to NGF with robust survival signaling. Cells expressing p75NTR alone, particularly when exposed to proNGF, can be pushed toward programmed cell death. The ratio of proNGF to mature NGF, and the relative expression of TrkA versus p75NTR, determines whether NGF acts as a trophic factor or a death signal in any given tissue context.
Understanding this complexity has direct implications for how peptides modulate neuroplasticity and why simple NGF supplementation strategies have repeatedly failed.
NGF and Pain: Why Blocking It Became a Billion-Dollar Bet
NGF is one of the most potent endogenous pain-sensitizing molecules. Injecting microgram quantities of NGF into human skin produces prolonged hyperalgesia lasting days to weeks. This happens because NGF sensitizes nociceptors through TrkA-mediated phosphorylation of ion channels including TRPV1, the capsaicin receptor, lowering the threshold for pain-generating stimuli.[5]
NGF levels are elevated in multiple chronic pain conditions: osteoarthritis synovial fluid, interstitial cystitis bladder tissue, and chronic low back pain. This observation led pharmaceutical companies to pursue anti-NGF antibodies as a new class of analgesics.
Tanezumab: Rise and Fall
Tanezumab, a humanized monoclonal antibody that binds and neutralizes NGF, initially showed promising results. In phase 2 and 3 trials for osteoarthritis, the 5 mg dose met all three co-primary endpoints at 24 weeks, demonstrating statistically significant improvement in pain, physical function, and patient global assessment compared to placebo.[6]
Research into the mechanisms behind anti-NGF pain relief revealed involvement of endogenous opioid peptide systems, suggesting that NGF blockade does not simply remove a pain signal but alters the broader pain-processing network.[7]
The program collapsed over safety. During phase 2 and 3 development, 87 patients reported adverse events classified as osteonecrosis. The FDA placed a partial clinical hold on tanezumab studies in 2010. The risk was highest when tanezumab was combined with NSAIDs. In October 2021, Pfizer and Eli Lilly discontinued the entire tanezumab development program after regulatory reviews by both the FDA and EMA concluded the benefit-risk profile was unfavorable.
The tanezumab story illustrates a recurring theme in NGF therapeutics: the molecule's biology is too intertwined with fundamental tissue maintenance processes to be safely manipulated systemically.
NGF and Alzheimer's Disease: The Cholinergic Hypothesis
Basal forebrain cholinergic neurons, which project widely throughout the cortex and hippocampus, depend on NGF for survival and function. These neurons degenerate early and severely in Alzheimer's disease. The cholinergic hypothesis of AD proposed that restoring NGF supply to these neurons could slow or halt cognitive decline.[8]
Gene Therapy Trials
The challenge with delivering NGF to the brain is that the 26 kDa protein does not cross the blood-brain barrier. This forced researchers toward invasive delivery strategies.
A phase 1 trial by Tuszynski and colleagues implanted autologous fibroblasts genetically modified to secrete NGF into the basal forebrain of eight patients with mild AD. After a mean follow-up of 22 months in six subjects, no long-term adverse effects occurred, and cognitive decline rates appeared to slow.[9] Post-mortem analysis of subjects who died years after treatment confirmed that cholinergic neurons had sprouted toward the NGF source, demonstrating biological activity.
A subsequent phase 2 trial tested AAV2-NGF (adeno-associated viral vector delivering the NGF gene) in 49 patients with mild to moderate AD via stereotactic brain injection. The treatment was well tolerated but did not improve clinical outcomes or affect AD biomarkers compared to sham surgery.[10]
Post-hoc analysis suggested that vector delivery may not have reached sufficient target tissue. Whether the failure reflects an inadequate delivery approach, insufficient NGF expression levels, or a fundamental limitation of the cholinergic hypothesis remains debated. Research into how neurogenesis and peptides interact continues to inform new delivery strategies.
Cenegermin: The First FDA-Approved NGF Drug
While brain delivery remained unsolved, a topical application succeeded. Cenegermin (brand name Oxervate) is recombinant human NGF formulated as a 0.002% ophthalmic solution. The FDA approved it in 2018 for neurotrophic keratitis, a rare degenerative corneal condition caused by damage to corneal nerves.
In the pivotal clinical trials, 69.6% of patients treated with cenegermin achieved complete corneal healing within 8 weeks, compared to 29.4% of patients receiving vehicle alone. Treatment involved instilling one drop six times daily for 8 weeks.[11]
Cenegermin works because the cornea is directly accessible. The drug does not need to cross biological barriers or reach distant targets. NGF binds TrkA receptors on corneal epithelial cells and nerve terminals, promoting both epithelial wound healing and sensory nerve regeneration. This dual action addresses both the structural damage and the underlying nerve dysfunction that characterizes neurotrophic keratitis.
Long-term follow-up data have confirmed that cenegermin's effects persist well beyond the 8-week treatment period. Many patients maintained corneal integrity for months to years after a single treatment course. The drug represents proof of concept that NGF can be therapeutically useful when the delivery problem is solved.
Research into improving NGF's delivery for other ophthalmic applications has explored conjugation with cell-penetrating peptides. One study found that coupling NGF with a cell-penetrating peptide and delivering it as an eye drop enhanced neuroprotective activity in retinal ganglion cells compared to unconjugated NGF.[12]
NGF and Other Peptide Systems
Several peptide-based therapeutics interact with the NGF signaling axis, offering indirect strategies for modulating neurotrophic support.
Cerebrolysin and NGF
Cerebrolysin, a peptide preparation derived from porcine brain proteins, has demonstrated NGF-like neurotrophic activity since the 1990s. A 2017 study in aging rats showed that cerebrolysin treatment increased NGF protein levels and TrkA expression in the hippocampus and basal forebrain, regions critical for memory and cholinergic function.[13] A comprehensive 2023 review of neurotrophic factor modulation confirmed that cerebrolysin's neurotrophic activity involves upregulation of both NGF and BDNF in brain tissue, with clinical benefits observed in dementia, stroke, and traumatic brain injury trials.[14]
Semax and NGF Upregulation
Semax, a synthetic analog of ACTH(4-10), specifically binds and increases levels of both NGF and BDNF in rat hippocampus and basal forebrain. A 2006 study found that Semax administration increased NGF mRNA expression and protein levels in brain regions relevant to memory and cognitive function.[15] This pharmacological approach to boosting endogenous NGF avoids the delivery barriers that have plagued direct NGF administration.
Thymosin Beta 4 and Neurotrophic Pathways
Thymosin beta 4 (TB4), a 43-amino-acid peptide primarily known for wound healing, has shown neuroprotective activity through neurotrophic factor signaling. A 2023 study demonstrated that TB4 protected hippocampal neurons from prion protein-induced toxicity by activating neurotrophic factor pathways, including upregulation of NGF signaling cascades.[16]
NGF and Neuropeptide Crosstalk
NGF does not operate in isolation from other signaling peptides. Keratinocytes exposed to neuropeptides such as substance P and CGRP respond by increasing NGF production, creating a positive feedback loop between sensory nerve activation and neurotrophic support in peripheral tissues.[17] This crosstalk is relevant to both wound healing and chronic pain conditions.
Recent research has explored NGF-inspired peptide design. A 2026 study derived short peptides from snake venom NGF sequences and tested their neuroprotective activity against insecticide-induced neurotoxicity, demonstrating that NGF-mimetic peptide fragments can retain biological activity without the full protein.[18] This approach parallels other efforts to develop neuroprotective peptides that mimic the activity of larger neurotrophic proteins.
Where NGF Research Stands
NGF's therapeutic track record is mixed. One FDA-approved drug in ophthalmology. A discontinued anti-NGF pain program. A failed Alzheimer's gene therapy trial. Several peptide-based approaches that modulate NGF indirectly.
The fundamental challenge remains delivery. NGF does not cross the blood-brain barrier, which limits CNS applications to invasive approaches. Systemic administration causes hyperalgesia through TrkA activation on sensory neurons. The proNGF/mature NGF balance adds another layer of complexity: simply flooding tissue with exogenous NGF does not recapitulate the precise spatiotemporal signaling that endogenous NGF provides.
Current research directions include NGF-mimetic small molecules that can cross the BBB, encapsulated cell biodelivery devices that secrete NGF directly into the brain, and peptide fragments that retain neurotrophic activity without full-length protein. The discovery that other peptides like Dihexa can activate related neurotrophic pathways has expanded the therapeutic landscape beyond direct NGF replacement.
The field that Levi-Montalcini launched in the 1950s continues to evolve. NGF itself may never become a broadly used therapeutic, but the signaling principles it revealed underpin every modern approach to neurotrophic peptide medicine.
The Bottom Line
NGF was the first neurotrophin discovered and remains one of the best-characterized signaling proteins in neuroscience. Its clinical translation has been limited by delivery barriers and safety concerns from systemic exposure. Cenegermin for neurotrophic keratitis stands as the sole FDA-approved NGF drug, while anti-NGF antibodies for pain and NGF gene therapy for Alzheimer's disease have both failed in late-stage development. Peptide-based approaches that modulate endogenous NGF levels, rather than delivering exogenous protein, may represent the most viable path forward.